Lipid rafts: A signalling platform linking lipoprotein metabolism to atherogenesis

Atherosclerosis

Volumn 221, Issue 2, 2012, Pages 303-310

  Lemaire Ewing, Stéphanie ^a   Lagrost, Laurent ^a   Néel, Dominique ^a  

^a boulevard Jeanne d'Arc   (France)

Author keywords

Atherosclerosis; Cholesterol; Lipid raft; Lipoprotein; Oxysterol; Signal transduction

Indexed keywords

25 HYDROXYCHOLESTEROL; 7 OXOCHOLESTEROL; 7BETA HYDROXYCHOLESTEROL; ABC TRANSPORTER A1; APOLIPOPROTEIN A1; CAVEOLIN 1; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EPIDERMAL GROWTH FACTOR; FAS ANTIGEN; GELATINASE A; GELATINASE B; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE B; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSIENT RECEPTOR POTENTIAL CHANNEL 1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

APOPTOSIS; ATHEROGENESIS; ATHEROMA; ATHEROSCLEROSIS; CALCIUM SIGNALING; CALCIUM TRANSPORT; CAVEOLA; CAVEOLIN SCAFFOLDING DOMAIN; CELL MIGRATION; CELL PROLIFERATION; CHOLESTEROL METABOLISM; DISEASE COURSE; DISEASE SEVERITY; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; INTRACELLULAR SIGNALING; LIPID RAFT; LIPOPROTEIN METABOLISM; MACROPHAGE; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN TRANSPORT; REVIEW; SMOOTH MUSCLE FIBER; T LYMPHOCYTE ACTIVATION; TRANSCYTOSIS; UPREGULATION; VASCULAR SMOOTH MUSCLE;

ANIMALS; ATHEROSCLEROSIS; BLOOD VESSELS; CHOLESTEROL; HUMANS; INFLAMMATION MEDIATORS; LIPOPROTEINS; MEMBRANE MICRODOMAINS; SIGNAL TRANSDUCTION;

EID: 84858703061     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.10.016     Document Type: Review

References (129)

1. Brown D.A., London E. Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J Biol Chem 2000, 275:17221-17224.
2. Simons K., Ikonen E. Functional rafts in cell membranes. Nature 1997, 387:569-572.
3. Pike L.J. Lipid rafts: bringing order to chaos. J Lipid Res 2003, 44:655-667.
4. Hancock J.F. Lipid rafts: contentious only from simplistic standpoints. Nat Rev Mol Cell Biol 2006, 7:456-462.
5. Munro S. Lipid rafts: elusive or illusive?. Cell 2003, 115:377-388.
6. Lichtenberg D., Goñi F.M., Heerklotz H. Detergent-resistant membranes should not be identified with membrane rafts. Trends Biochem Sci 2005, 30:430-436.
7. Lingwood D., Simons K. Lipid rafts as a membrane organizing principle. Science 2010, 327:46-50.
8. Simons K., Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 2000, 1:31-39.
9. Gomez-Mouton C., Abad J.L., Mira E., et al. Segregation of leading edge and uropod components into specific lipid rafts during T cell polarization. Proc Natl Acad Sci U S A 2001, 98:9642-9647.
10. Triantafilou M., Miyake K., Golenbbock D.T., Triantafilou K. Mediators of innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell activation. J Cell Sci 2002, 115:2603-2611.
11. Harder T. Lipid raft domains and protein networks in T cell receptor signal transduction. Curr Opin Immunol 2004, 16:353-359.
12. Luo C., Wang K., Liu D., Li Y., Zhao Q. The functional roles of lipid rafts in T cell activation, immune diseases and HIV infection and prevention. Cell Mol Immunol 2008, 5:1-7.
13. Triantafilou M., Gamper F.G.J., Lepper P.M., et al. Lipopolysaccharides from atherosclerosis-associated bacteria antagonize TLR4, induce formation of TLR/1/CD36 complexes in lipid rafts and trigger TLR-induced inflammatory responses in human vascular endothelial cells. Cell Microbiol 2007, 9:2030-2039.
14. Triantafilou M., Morath S., Mackie A., Hartung T., Triantafilou K. Lateral diffusion of Toll-like receptors reveals that they are transiently confined within lipid rafts on the plasma membrane. J Cell Sci 2004, 117:4007-4014.
15. Vaino S., Heino S., Mansson J.E., et al. Dynamic association of human insulin receptor with lipid rafts in cells lacking caveolae. EMBO Rep 2002, 3:95-100.
16. Yang J., Zhang X., Wang J., et al. Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class 1 to and excluding growth and survival cytokine receptors from lipid rafts. Blood 2007, 110:3028-3035.
17. Parpal S., Karlsson M., Thorn H., Stralfors P. Cholesterol depletion disrupts caveolae and insulin receptor signalling for metabolic control via insulin receptor substrate-1, but not for mitogen-activated protein kinase control. J Biol Chem 2001, 276:9670-9678.
18. Mc Guire T.F., Corey S.J., Sebti S.M. Lovastatin inhibits platelets-derived growth factor (PDGF) stimulation of phosphatidylinositol3-kinase activity as well as association of p85 subunit to tyrosine phosphorylated PDGF receptor. J Biol Chem 1993, 268:22227-22230.
19. Patel H.H., Insel P.A. Lipid rafts and caveolae and their role in compartmentation of redox signaling. Antioxid Redox Signal 2009, 11:1357-1372.
20. Frank P.G., Pavlides S., Cheung M.W.C., Daumer K., Lisanti M.P. Role of caveolin-1 in the regulation of lipoprotein metabolism. Am J Physiol Cell Physiol 2008, 295:C242-C248.
21. Insel P.A., Patel H.H. Membrane rafts and caveolae in cardiovascular signaling. Curr Opin Nephrol Hypertens 2009, 18:50-56.
22. Sbaa E., Frerart F., Feron O. The double regulation of endothelial nitric oxide synthase by caveolae and caveolin: a paradox solved through the study of angiogenesis. Trends Cardiovascular Med 2005, 15:157-162.
23. Frank P.G., Lisanti M.P. Caveolin-1 and Caveolae in atherosclerosis: differential roles in fatty streak formation and neointimal hyperplasia. Curr Opin Lipidol 2004, 15:523-529.
24. Schubert W., Frank P.G., Razani B., Park D.S., Chow C.W., Lisanti M.P. Caveolae-deficient endothelial cells show defects in the uptake and transport of albumin in vivo. J Biol Chem 2001, 276:48619-48622.
25. Frank P.G., Lee H., Park D.S., Tandon N.N., Scherer P.E., Lisanti M.P. Genetic ablation of caveolin-1 confers protection against atherosclerosis. Arterioscler Thromb Vasc Biol 2004, 24:98-105.
26. Huber J., Vales A., Mitulovic G., et al. Oxidized membrane vesicles and blebs from apoptotic cells contain biologically active oxidized phospholipids that induce monocyte-endothelial interactions. Arterioscler Thromb Vasc Biol 2002, 22:101-107.
27. Clarke M.C., Figg N., Maguire J.J., et al. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat Med 2006, 12:1075-1080.
28. Mallat Z., Tedgui A. Current perspective on the role of apoptosis in atherothrombotic disease. Circ Res 2001, 88:998-1003.
29. Gautier E.L., Huby T., Witztum J.L., et al. Macrophage apoptosis exerts divergent effects on atherogenesis as a function of lesion stage. Circulation 2009, 119:1795-1804.
30. Kavurma M.M., Tan N.Y., Bennet M.R. Death receptors and their ligands in atherosclerosis. Arterioscler Thromb Vasc Biol 2008, 28:1694-1702.
31. Sata M., Walsh K. Oxidized LDL activates fas-mediated endothelial cell apoptosis. J Clin Invest 1998, 102:1682-1689.
32. Gajate C., Mollinedo F. The antitumor ether lipid ET-18-OCH (3) induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood 2001, 98:3860-3863.
33. Rho M.C., Kim Y.K., Chang J.S., et al. 7-ketocholesterol predisposes human aorta smooth muscle cells to Fas-mediated death. J Mol Cell Cardiol 2005, 39:823-832.
34. Andersson J., Libby P., Hansson G.K. Adaptative immunity and atherosclerosis. Clin Immunol 2010, 134:33-46.
35. Kabouridis P.S. Lipid rafts in T cell receptor signalling. Mol Membr Biol 2006, 23:49-57.
36. Rentero C., Zech T., Quinn C.M., et al. Functional implications of plasma membrane condensation for T cell activation. PLoS One 2008, 3(5):e2262. 1-14.
37. Shalhoub J., Falck-Hansen M.A., Davies A.H., Monaco C. Innate immunity and monocyte-macrophage activation in atherosclerosis. J Inflamm 2011, 8:9.
38. Monaco C., Gregan S.M., Navin T.J., Foxwell B.M.J., Davies A.H., Feldman M. Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis. Circulation 2009, 120:2462-2469.
39. Fernandez-Hernando C., Yu J., Suarez Y., Rahner C., et al. Genetic evidence supporting a critical role of endothelial caveolin-1 during the progression of atherosclerosis. Cell Metab 2009, 10:48-54.
40. Fernandez-Hernando C., Yu J., Suarez Y., Davalos A., Prendergast J., Sessa W.C. Endothelial-specific overexpression of caveolin-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 2010, 177:998-1003.
41. Kiely J.M., Hu Y., Garcia-Cardeña G., Gimbrone M.A. Lipid raft localization of cell surface E-selectin is required for ligation-induced activation of phospholipase Cγ. J Immunol 2003, 171:3216-3224.
42. Gaus K., Rodriguez M., Ruberu K.R., Gelissen I., et al. Domain specific lipid distribution in macrophage plasma membranes. J Lipid Res 2005, 46:1526-1538.
43. Hailemariam T.K., Huan C., Liu J., Li Z., et al. Sphingomyelin synthase 2 deficiency attenuates NFκB activation. Arterioscler Thromb Vasc Biol 2008, 28:1519-1526.
44. Rodriguez-Feo J.A., Hellings W.E., Moll F.L., De Vries J.P.P.M., et al. Caveolin-1 influences vascular protease activity and is a potential stabilizing factor in human atherosclerotic disease. PLoS One 2008, 3:e2612.
45. Chow A.K., Cena J., El-Yazbi A.F., Crawford B.D., et al. Caveolin-1 inhibits matrix metalloproteinase activity in the heart. J Mol Cell Cardiol 2007, 42:896-901.
46. Engelman J.A., Chu C., lin A., et al. Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain. FEBS Lett 1998, 428:205-211.
47. Goetze S., Xi X.P., Kawano Y., et al. TNF-alpha-induced migration of vascular smooth muscle cells is MAPK dependent. Hypertension 1999, 33:183-189.
48. Hassan G.S., Jasmin J.F., Schubert W., Frank P.G., Lisanti M.P. Caveolin-1 deficiency stimulates neointima formation during vascular injury. Biochemistry 2004, 43:8312-8321.
49. Schwencke C., Schmeisser A., Walter C., et al. Decreased caveolin-1 in atheroma: loss of antiproliferative control of vascular smooth muscle cells in atherosclerosis. Cardiovasc Res 2005, 68:128-135.
50. Vaya A., Martinez-Triguero M., Reganon E., et al. Erythrocyte membrane composition in patients with primary hypercholesterolemia. Clin Hemorheol Microcirc 2008, 40:289-294.
51. Sánchez-Wandelmer J., Dávalos A., Herrera E., et al. Inhibition of cholesterol biosynthesis disrupts lipid raft/caveolae and affects insulin receptor activation in 3T3-L1 preadipocytes. Biochim Biophys Acta 2009, 1788:1731-1739.
52. Roepstorff K., Thomsen P., Sandvig K., Van Deurs B. Sequestration of epidermal growth factor receptors in non caveolar lipid rafts inhibits ligand binding. J Biol Chem 2002, 277:18954-18960.
53. Chen C.L., Liu I.H., Fliesler S.J., Han X., Huang S.S., Huang J.S. Cholesterol suppresses cellular TGF-β responsiveness: implications in atherogenesis. J Cell Sci 2007, 120:3509-3521.
54. Pike L.J., Casey L. Cholesterol levels modulate EGF receptor-mediated signaling by altering receptor function and trafficking. Biochemistry 2002, 41:10315-10322.
55. Owens G.K., Geisterfer A.A., Yang Y.W., Komoriya A. Transforming growth factor β-induced growth inhibition and cellular hypertrophy in cultured vascular smooth muscle cells. J Cell Biol 1988, 107:771-780.
56. Gamble J.R., Khew-Goodall Y., Vadas M.A. Transforming growth factor β inhibits E-selectin expression on human endothelial cells. J Immunol 1993, 150:4494-4503.
57. Chen C.L., Huang S.S., Huang J.S. Cholesterol modulates cellular TGF-β responsiveness by altering TGF-β binding to TGF-β receptors. J Cell Physiol 2008, 215:223-233.
58. Mallat Z., Gojova A., Marchiol-Fournigault C., et al. Inhibition of transforming growth factor β signalling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res 2001, 89:930-934.
59. ++ entry and respiratory burst: correlations with calcium channel raft trafficking. J Immunol 2007, 178:5253-5261.
60. Baumruker T., Csonga R., Pursch E., et al. Activation of mast cells by incorporation of cholesterol into rafts. Intern Immunol 2003, 15:1207-1218.
61. Preston Mason R., Tulenko T.N., Jacob R.F. Direct evidence for cholesterol crystalline domains in biological membranes: role in human pathobiology. Biochim Biophys Acta 2003, 1610:198-207.
62. Preston Mason R., Jacob R.F. Membrane microdomains and vascular biology. Emerging role in atherogenesis. Circulation 2003, 107:2270-2273.
63. Witztum J.L., Steinberg D. Role of oxidized low-density lipoproteins in atherogenesis. J Clin Invest 1991, 88:1785-1792.
64. Yasunobu Y., Hayashi K., Shingu T., Yamagata T., Kajiyama G., Kambe M. Coronary atherosclerosis and oxidative stress as reflected by autoantibodies against oxidized low-density lipoprotein and oxysterols. Atherosclerosis 2001, 155:445-453.
65. Lordan S., Mackrill J.J., O'Brien N.M. Oxysterols and mechanisms of apoptotic signalling: implication in the pathology of degenerative diseases. J Nutr Biochem 2009, 20:321-336.
66. Poli G., Sottero B., Gargiulo S., Leonarduzzi G. Cholesterol oxidation products in the vascular remodeling due to atherosclerosis. Mol Aspects Med 2009, 30:180-189.
67. Leonarduzzi G., Sottero B., Poli G. Oxidized products of cholesterol: dietary and metabolic origin, and proatherosclerotic effects. J Nutr Biochem 2002, 13:700-710.
68. Deckert V., Perségol L., Viens L., et al. Inhibitors of arterial relaxation among components of human oxidized low density lipoproteins. Cholesterol derivatives oxidized in position 7 are potent inhibitors of endothelium dependent relaxation. Circulation 1997, 95:723-731.
69. Lemaire S., Lizard G., Monier S., et al. Different patterns of IL-1β, adhesion molecule expression and apoptosis induction in human endothelial cells treated with 7α-, 7β-hydroxycholesterol or 7-ketocholesterol. FEBS Lett 1998, 440:434-439.
70. Liu Y., Hultén L.M., Wiklund O. Macrophages isolated from human atherosclerotic plaques produce IL-8 and oxysterols may have a regulatory function for IL-8 production. Arterioscler Thromb Vasc Biol 1997, 17:317-323.
71. Rydberg E.K., Salomonsson L., Hulten L.M., et al. Hypoxia increases 25-hydroxycholesterol-induced interleukin-8 protein secretion in human macrophages. Atherosclerosis 2003, 170:245-252.
72. Lemaire-Ewing S., Prunet C., Montange T., et al. Comparison of the cytotoxic, pro-oxidant and proinflammatory characteristics of different oxysterols. Cell Biol Toxicol 2005, 21:97-114.
73. Prunet C., Montange T., Véjux A., et al. Multiplexed flux cytometric analysis of pro- and anti-inflammatory cytokines in the culture media of oxysterol treated human monocytic cells and in the sera of atherosclerotic patients. Cytometry 2006, 69:359-373.
74. Leonarduzzi G., Gamba P., Sottero B., et al. Oxysterol-induced up regulation of MCP1 expression and synthesis in macrophage cells. Free Radic Biol Med 2005, 39:1152-1161.
75. ++ channel blockers verapamil and nifedipine inhibit apoptosis induced by 25-hydroxycholesterol in human aortic smooth muscle cells. J Lipid Res 1997, 38:2049-2061.
76. Clare K., Hardwick S.J., Carpenter K.L., Weeratunge N., Mitchinson M.J. Toxicity of oxysterols to human monocytes-macrophages. Atherosclerosis 1995, 118:67-75.
77. Garcia-Cruset S., Carpenter K.L.H., Guardiola F., Mitchinson M.J. Oxysterols in cap and core of human advanced atherosclerotic lesions. Free Radic Res 1999, 30:341-350.
78. Garcia-Cruset S., Carpenter K.L.H., Guardiola F., Stein B.K., Mitchinson M.J. Oxysterol profiles of normal arteries, fatty streaks and advanced lesions. Free Radic Res 2001, 35:31-41.
79. Geng Y.J., Libby P. Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin 1-β converting enzyme. Am J Pathol 1995, 147:251-266.
80. Ohtsuka M., Miyashita Y., Shirai K. Lipids deposited in human atheromatous lesions induce apoptosis of human vascular smooth muscle cells. J Atheroscler Thromb 2006, 13:256-262.
81. Wang J., Mehga, London E. Relationship between sterol/steroid structure and participation in ordered lipid domains (lipid rafts): implication for lipid raft structure and function. Biochemistry 2004, 43:1010-1018.
82. Beattie M.E., Veatch S.L., Stottrup B.L., Keller S.L. Sterol structure determines miscibility versus melting transitions in lipid vesicles. Biophys J 2005, 89:1760-1768.
83. Massey J.B., Pownall H.J. The polar nature of 7-ketocholesterol determines its location within membrane domains and the kinetics of membrane microsolubilization by apolipoprotein A1. Biochemistry 2005, 44:10423-10433.
84. Gaus K., Kritharides L., Schmitz G., et al. Apolipoprotein A-1 interaction with plasma membrane lipid rafts controls cholesterol export from macrophages. FASEB J 2004, 18:574-576.
85. Gaus K., Dean R.T., Kritharides L., Jessup W. Inhibition of cholesterol efflux by 7-ketocholesterol: comparison between cells, plasma membrane vesicules and liposomes as cholesterol donors. Biochemistry 2001, 40:13002-13014.
86. Berthier A., Lemaire-Ewing S., Prunet C., et al. Involvement of a calcium-dependent dephosphorylation of BAD associated with the localization of Trpc-1 within lipid rafts in 7-ketocholesterol-induced THP-1 cells apoptosis. Cell Death Differ 2004, 11:897-905.
87. Freeman N.E., Rusinol A.E., Linton M., et al. Acyl-coenzyme A: cholesterol acyltransferase promotes oxidized LDL/oxysterol-induced apoptosis in macrophages. J Lipid Res 2005, 46:1933-1943.
88. Berthier A., Lemaire-Ewing S., Prunet C., et al. 7-Ketocholesterol-induced apoptosis. Involvement of several pro-apoptotic but also anti-apoptotic calcium-dependent transduction pathways. FEBS J 2005, 272:3093-3104.
89. Lemaire-Ewing S., Berthier A., Royer M.C, et al. 7-β-Hydroxycholesterol and 25-hydroxycholesterol-induced interleukin-8 secretion involves a calcium-dependent activation of c-fos via the ERK1/2 signaling pathway in THP-1 cells. Cell Biol Toxicol 2009, 25:127-139.
90. Pani B., Singh B.B. Lipid rafts/caveolae as microdomains of calcium signaling. Cell Calcium 2009, 45:625-633.
91. Massey J.B. Membrane and protein interactions of oxysterols. Curr Opin Lipidol 2006, 17:296-301.
92. Pedruzzi E., Guichard C., Ollivier V., et al. NAD(P)H oxidase Nox-4 mediates 7-ketocholesterol-induced endoplasmic reticulum stress and apoptosis in human aortic smooth muscle cells. Mol Cell Biol 2004, 24:10703-10717.
93. Royer M.C., Lemaire-Ewing S., Desrumaux C., et al. 7-Ketocholesterol incorporation into sphingolipid/cholesterol-enriched (lipid raft) domains is impaired by vitamin E: a specific role for α-tocopherol with consequences on cell death. J Biol Chem 2009, 284:15826-15834.
94. Lasserre R., Guo X.J., Conchaunaud F., et al. Raft nanodomains contribute to akt/PKB plasma membrane recruitment and activation. Nat Chem Biol 2008, 4:538-547.
95. Fukunaga-Takenaka R., Shirai Y., Yagi K., et al. Importance of chroman ring and tyrosine phosphorylation in the subtype specific translocation and activation of diacylglycerol kinase α by d-α-tocopherol. Genes Cells 2005, 10:311-319.
96. Byfield F.J., Tikku S., Rothblat G.H., Gooch K.J., Levitan I. OxLDL increases endothelial stiffness, force generation, and network formation. J Lipid Res 2006, 47:715-723.
97. Yu B.L., Wang S.H., Peng D.Q., Zhao S.P. HDL and immunomodulation: an emerging role of HDL against atherosclerosis. Immunol Cell Biol 2010, 88:285-290.
98. Baker P.V., Rye K.A., Gamble J.R., Vadas M.A., Barter P.J. Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion-1 in human umbilical vein endothelial cells. J Lipid Res 1999, 40:345-353.
99. Cockerill G.W., Rye K.A., Gamble J.R., Vadas M.A., Barter P.J. High density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995, 15:1987-1994.
100. Tellier E., Canault M., Poggi M., et al. HDLs activate ADAM17-dependent shedding. J Cell Physiol 2008, 214:687-693.
101. Barter P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., Fogelman A.M. Anti-inflammatory properties of HDL. Circ Res 2004, 95:764-772.
102. Murphy A.J., Woolard K.J., Hoang A., et al. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol 2008, 28:2071-2077.
103. Bultel S., Helin L., Clavey V., et al. Liver X receptor activation induces the uptake of cholesteryl esters from high density lipoproteins in primary human macrophages. Arterioscler Thromb Vasc Biol 2008, 28:2288-2295.
104. Kinoshita M., Fujita M., Usui S., et al. Scavenger receptor type BI potentiates reverse cholesterol transport system by removing cholesterol ester from HDL. Atherosclerosis 2004, 173:197-202.
105. Jeffrey Field F., Watt K., Mathur S.N. Origins of intestinal ABCA1-mediated HDL-cholesterol. J Lipid Res 2008, 49:2605-2619.
106. Fitzgerald M.L., Mujawar Z., Tamehiro N. ABC transporter, atherosclerosis and inflammation. Atherosclerosis 2010, 211:361-370.
107. Francone O.L., Royer L., Boucher G., et al. Increased cholesterol deposition, expression of scavenger receptors, and response to chemo tactic factors in Abca1-deficient macrophages. Arterioscler Thromb Vasc Biol 2005, 25:1198-1205.
108. Yvan-Charvet L., Ranaletta M., Wang N., et al. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J Clin Invest 2007, 117:3900-3908.
109. Landry Y.D., Denis M., Nandi S., Bell S., Vaughan A.M., Xiaohui Z. ATP-binding Cassette Transporter A1 expression disrupts raft membrane microdomains through its ATPase-related functions. J Biol Chem 2006, 281:36091-36101.
110. Vaughan A.M., Oram J.F. ABCA1 redistributes membrane cholesterol independent of apolipoprotein interactions. J Lipid Res 2003, 44:1373-1380.
111. Zhu X., Lee J.Y., Timmins J.M., et al. Increased cellular free cholesterol in macrophage-specific Abca 1 knock-out mice enhances pro-inflammatory response of macrophages. J Biol Chem 2008, 283:22930-22941.
112. Zhu X., Owen J.S., Wilson M.D., et al. Macrophage ABCA1 reduces MyD88-dependent Toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol. J Lipid Res 2010, 51:3196-3206.
113. Lin Y.C., Ma C., Hsu W.C., Lo H.F., Yang V.C. Molecular interaction between caveolin-1 and ABCA1 on high-density lipoprotein-mediated cholesterol efflux in aortic endothelial cells. Cardiovasc Res 2007, 75:575-583.
114. Frank P.G., Marcel Y.L., Connelly M.A., et al. Stabilization of caveolin-1 by cellular cholesterol and scavenger receptor class B type I. Biochemistry 2002, 41:11931-11940.
115. Wang L., Connelly M.A., Ostermeyer A.G., Chen H.H., Williams Dl, Brown D.A. Caveolin-1 does not affect SR-BI-mediated cholesterol efflux or selective uptake of cholesteryl ester in two cell lines. J Lipid Res 2003, 44:807-815.
116. Matveev S., Uittenbogaard A., van Der Westhuyzen D., Smart E.J. Caveolin-1 negatively regulates SR-BI mediated selective uptake of high-density lipoprotein-derived cholesteryl ester. Eur J Biochem 2001, 268:5609-5616.
117. Briand O., Lestavel S., Pilon A., Torpier G., Fruchart J.C., Clavey V. SR-BI does not require raft/caveolae localisation for cholesteryl ester selective uptake in the human adrenal cell line NCI-H295R. Biochim Biophys Acta 2003, 1631:42-50.
118. Peshavariya H., Dusting G.J., Di Bartolo B., Rye K.A., Barter P.J., Jiang F. Reconstituted high density lipoprotein suppresses leukocytes NADPH oxidase activation by disrupting lipid rafts. Free Radic Res 2009, 10:1-11.
119. Zhang A.Y., Yi F., Zhang G., Gulbins E., Li P.L. Lipid raft clustering and redox signaling platform formation in coronary arterial endothelial cells. Hypertension 2006, 47:74-80.
120. Hayashi T.R., Juliet P.A., Myasaki A., Ignarro L.J., Iguchi A. High glucose down regulates the number of caveolae in monocytes through oxidative stress from NADPH oxidase: implication for atherosclerosis. Biochem Biophys Acta 2007, 1772:364-372.
121. Deckert V., Brunet A., Lantoine F., et al. Inhibition by cholesterol oxides of NO release from human vascular endothelial cells. Arterioscler Thromb Vasc Biol 1998, 18:1054-1060.
122. Preston Mason R., Walter M.F., Jacob R.F. Effects of HMG-CoA reductase inhibitors on endothelial function. Role of microdomains and oxidative stress. Circulation 2004, 109:34-41.
123. Feron O., Dessy C., Desager J.P., Balligand J.L. Hydroxy-methylglutaryl-coenzymeA reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001, 103:113-118.
124. Terasaka N., Yu S., Yvan-Charvet L., et al. ABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol diet. J Clin Invest 2008, 118:3701-3713.
125. Terasaka N., Westerterp M., Koetsveld J., et al. ATP-binding cassette transporter G1 and high-density lipoprotein promote endothelial NO synthesis through a decrease in the interaction of caveolin-1 and endothelial NO synthase. Arterioscler Thromb Vasc Biol 2010, 30:2219-2225.
126. Hillyard D.Z., Jardine A.G., McDonald K.J., Cameron A.J.M. Fluvastatin inhibits raft dependent Fcγ receptor signalling in human monocytes. Atherosclerosis 2004, 172:219-228.
127. Hillyard D.Z., Nutt C.D., Thomson J., et al. Statins inhibit NK cell cytotoxicity by membrane raft depletion rather than inhibition of isoprenylation. Atherosclerosis 2007, 191:319-325.
128. Schonbeck U., Sukhova G.K., Shimizu K., Mach F., Libby P. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci U S A 2000, 97:7453-7458.
129. Xia M., Ling W., Zhu H., et al. Anthocyanin prevents CD40-activated proinflammatory signaling in endothelial cells by regulating cholesterol distribution. Arterioscler Thromb Vasc Biol 2007, 27:519-524.